Table 1 Patient demographics and baseline disease characteristics

CharacteristicPlacebo, n = 84Pregabalin, n = 89All patients, n = 173
* n = 88 for the pregabalin-treated group.
PHN = postherpetic neuralgia.
Sex, n (%)
    Men44 (52.4)37 (41.6)81 (46.8)
    Women40 (47.6)52 (58.4)92 (53.2)
Race, n (%)
    White82 (97.6)82 (92.1)164 (94.8)
    Hispanic1 (1.2)6 (6.7)7 (4.0)
    Asian or Pacific Islander1 (1.2)1 (1.1)2 (1.2)
Age, y, mean (SD)70.5 (11.3)72.4 (10.5)71.5 (10.9)
Age, y, n (%)
    18–6417 (20.2)15 (16.9)32 (18.5)
    ≥6567 (79.8)74 (83.1)141 (81.5)
Weight, kg, mean (SD)79.8 (16.7)74.8 (13.4)*77.2 (15.3)
Estimated creatinine clearance, mL/min, mean (SD)80.3 (27.3)72.9 (27.5)76.5 (27.6)
Creatinine clearance strata, n (%)
    Low (>30, ≤60 mL/min)25 (29.8)30 (33.7)55 (31.8)
    Normal (>60 mL/min)59 (70.2)59 (66.3)118 (68.2)
Duration of PHN, mo, mean (SD)34.4 (36.7)33.3 (35.4)33.8 (35.9)
Predominantly affected dermatome, n (%)
    Trigeminal22 (26.2)18 (20.2)40 (23.1)
    Cervical6 (7.1)9 (10.1)15 (8.7)
    Thoracic41 (48.8)42 (47.2)83 (48.0)
    Lumbar11 (13.1)16 (18.0)27 (15.6)
    Sacral4 (4.8)4 (4.5)8 (4.6)
Baseline mean pain score (SD)6.4 (1.5)6.3 (1.4)6.4 (1.5)